Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Prevention of Chemotherapy Induced Nausea and Vomiting Age: Adult |
Dose: orally – 125 mg Frequency: once Duration: 1 hour prior to chemotherapy treatment (Day 1) Note: Given for 3 days as part of the chemotherapy-induced nausea and vomiting (CINV) regimen that includes a corticosteroid and a 5-HT3 antagonist. |
|
Indication: Prevention of Chemotherapy Induced Nausea and Vomiting Age: Adult |
Dose: orally – 80 mg Frequency: once daily in the morning Duration: Days 2 and 3 Note: Given for 3 days as part of the chemotherapy-induced nausea and vomiting (CINV) regimen that includes a corticosteroid and a 5-HT3 antagonist. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chemotherapy-Induced Nausea and Vomiting Age: less than 6 months Condition: Oral suspension |
Dose: Oral suspension – Safety and efficacy not established |
|
Indication: Chemotherapy-Induced Nausea and Vomiting Age: less than 12 years Condition: Capsule |
Dose: Capsule – Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Severe (Creatinine Clearance less than 30 mL/min) |
Dose: Oral – Not specified Note: Decreased Area Under the Curve of total aprepitant (unbound and protein bound) by 21% and peak plasma concentration decreased by 32%, compared to healthy subjects (Creatinine Clearance greater than 80 mL/min) |
|
Condition: End-stage renal disease undergoing hemodialysis |
Dose: Oral – Not specified Note: Decreased Area Under the Curve of total aprepitant by 42% and peak plasma concentration decreased by 32% |
Administration
- Can be taken with or without food
- Take as prescribed
Side Effect
- Headache
- Asthenia/fatigue
- Anorexia
- Constipation
- Diarrhea
- Nausea
- Alopecia
- Hiccups
- Dizziness
- Insomnia
- Bradycardia
- Hypotension
- Pharyngolargeal pain
- Mucosal inflammation
- Stomatitis
- Dyspepsia
- Anemia
- Neutropenia
- Hot flash
- Pruritus
- Dehydration
- Fever
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 inducers
|
May reduce efficacy of Aprepitant
|
|
Phenytoin, Tolbutamide, Warfarin
|
May decrease concentrations
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Risk of allergic reaction
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.